ADC Therapeutics said Chief Executive Officer Ameet Mallik will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on Friday, September 11, 2026, at 9:10 a.m. ET. The live webcast will be available through the Events & Presentations page in the Investors section of the company’s website, with a replay expected to remain available for approximately 30 days. The Lausanne-based commercial-stage biotechnology company focuses on antibody-drug conjugates and its lead product, ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC. ZYNLONTA has accelerated approval from the FDA and conditional approval from the European Commission for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The product is also being developed in combination regimens and earlier lines of treatment.